抗体创新引领突破:中国抗体制药研发与资本布局双轮驱动

报告大厅
May 15

中国报告大厅网讯,近期港股上市公司中国抗体制药(03681)通过股权配售完成1.24亿港元融资,加速推进其核心药物SM17的研发进程。作为聚焦单克隆抗体药物开发的生物科技企业,公司凭借创新疗法管线和差异化研发策略,在免疫性疾病治疗领域展现出强劲发展潜力。此次融资后,公司将重点布局特应性皮炎等适应症新药研发,并持续完善覆盖多疾病的生物制剂产品矩阵。  一、全球首创抗IL25R抗体SM17开辟特应...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10